P. Carpino

发表

Structural basis for AMPK activation: natural and synthetic ligands regulate kinase activity from opposite poles by different molecular mechanisms.

R. Kurumbail, M. Harris, Hong Wang, 2014, Structure.

Dihydropyridines: a new class of angiotensin II antagonists

K. W. Hoover, M. Mangiapane, M. Burkard, 1994 .

Mechanistic characterization of a 2-thioxanthine myeloperoxidase inhibitor and selectivity assessment utilizing click chemistry--activity-based protein profiling.

B. Cravatt, A. Speers, Kay Ahn, 2013, Biochemistry.

A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation.

P. Loria, T. Rolph, M. Boehm, 2016, Cell chemical biology.

A conformationally restrained series of AT1-selective angiotensin II antagonists

P. Carpino, S. Sneddon, Jardine Paul da Silva, 1994 .

MAP4K4 Is a Threonine Kinase That Phosphorylates FARP1.

L. Buckbinder, K. Stone, Adam G Schwaid, 2015, ACS chemical biology.

Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK Inhibitors.

A. Carlo, M. Boehm, K. J. Filipski, 2018, ACS medicinal chemistry letters.

Melanocortin-4 receptor modulators for the treatment of obesity: a patent analysis (2008-2014).

Esther C Y Lee, P. Carpino, 2015, Pharmaceutical patent analyst.

Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies

David A. Price, V. M. Jackson, P. Carpino, 2014, Expert opinion on investigational drugs.

Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases.

A. Kalgutkar, T. Maurer, J. Warmus, 2015, Journal of medicinal chemistry.

Discovery of Selective Small Molecule Inhibitors of Monoacylglycerol Acyltransferase 3.

C. C. Jorgensen, Hao Sun, M. Boehm, 2015, Journal of medicinal chemistry.

Recent developments in ghrelin receptor (GHS-R1a) agonists and antagonists

P. Carpino, 2002 .

Diabetes area patent participation analysis – part II: years 2011-2016

Matthew E. Crawford, M. Boehm, Jamie E. Moscovitz, 2018, Expert opinion on therapeutic patents.

Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience.

B. Maron, M. Maron, E. Rowin, 2017, Annals of cardiothoracic surgery.

New bicyclic cannabinoid receptor-1 (CB1-R) antagonists.

D. Scott, P. Iredale, S. Sakya, 2006, Bioorganic & medicinal chemistry letters.

Outcomes Over Follow-up ≥10 Years After Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.

B. Maron, M. Maron, E. Rowin, 2021, The American journal of cardiology.

Revascularization Options for Ischemic Cardiomyopathy: On-Pump and Off-Pump Coronary Artery Bypass Surgery

K. Khabbaz, D. DeNofrio, P. Carpino, 2004, Cardiology.

Modulators of the ghrelin system as potential treatments for obesity and diabetes

G. Ho, P. Carpino, Guyu Ho, 2008 .

Preclinical pharmacology of CP-424,391, and orally active pyrazolinone-piperidine growth hormone secretagogue

S. Toler, B. Lefker, J. A. Ragan, 2001, Endocrine.

Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs). Discovery of capromorelin.

S. Toler, B. Lefker, J. A. Ragan, 2003, Bioorganic & medicinal chemistry.

A simplified synthesis of (+)-brefeldin A

E. Corey, P. Carpino, 1990 .

Preclinical pharmacology of CP-424,391, an orally active pyrazolinone-piperidine [correction of pyrazolidinone-piperidine] growth hormone secretagogue.

S. Toler, D. Thompson, B. Lefker, 2001, Endocrine.

Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) Receptor Antagonist

D. Scott, P. Iredale, Xingrong Liu, 2010, BMC pharmacology.

Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity.

D. Scott, P. Iredale, C. Nduaka, 2009, Journal of medicinal chemistry.

Discovery and Biological Characterization of Capromorelin Analogues with Extended Half‐Lives

P. Carpino, 2003 .

A new enantiospecific route to the pseudopterosins

E. Corey, P. Carpino, 1990 .

Enantiospecific total synthesis of pseudopterosins A and E

E. Corey, P. Carpino, 1989 .

Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents.

D. Scott, P. Iredale, R. L. Dow, 2012, ACS medicinal chemistry letters.

New approaches to the synthesis of trans-alkene isosteres of dipeptides

A. Spaltenstein, P. Carpino, P. B. Hopkins, 1987 .

Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor.

Peter Cornelius, Eunsun Lee, D. Scott, 2012, Bioorganic & medicinal chemistry letters.

Allylic selenides in organic synthesis: new methods for the synthesis of allylic amines

J. Fitzner, A. Spaltenstein, R. G. Shea, 1986 .

A new synthesis of secondary allylic aliphatic and aromatic amines

A. Spaltenstein, P. Carpino, P. B. Hopkins, 1986 .

Latest approaches for the treatment of obesity

J. Fortin, M. Rives, A. Loomis, 2015, Expert opinion on drug discovery.

Beyond PPARs and Metformin: New Insulin Sensitizers for the Treatment of Type 2 Diabetes

D. Hepworth, P. Carpino, 2012 .

Review of companies and drug classes in the 2007-2011 antihypertensive patent literature.

D. Flynn, P. Carpino, Declan Flynn, 2012, Pharmaceutical patent analyst.

Discovery and evaluation of pyrazolo[1,5-a]pyrimidines as neuropeptide Y1 receptor antagonists.

T. Maurer, D. Hargrove, C. Mack, 2011, Bioorganic & medicinal chemistry letters.

Deconstruction of activity-dependent covalent modification of heme in human neutrophil myeloperoxidase by multistage mass spectrometry (MS(4)).

K. Geoghegan, F. Vajdos, Xidong Feng, 2012, Biochemistry.

Patent focus on new anti-obesity agents: September 1999 - February 2000

P. Carpino, 2000 .

Expert Opinion on Therapeutic Patents

P. Carpino, 2000 .

Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles.

D. Scott, P. Iredale, R. L. Dow, 2009, Bioorganic & medicinal chemistry letters.

Development of a selective activity-based probe for glycosylated LIPA.

Adam G Schwaid, M. Tu, F. Rajamohan, 2016, Bioorganic & medicinal chemistry letters.

Diabetes area participation analysis: a review of companies and targets described in the 2008 – 2010 patent literature

Bryan Goodwin, B. Goodwin, Philip A Carpino, 2010, Expert opinion on therapeutic patents.

Primary Lymphoma of the Heart

A. Tischler, Karl B. Coyner, N. Pandian, 2005 .

A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification.

A. Mathiowetz, J. Fortin, D. Hepworth, 2014, Nature chemical biology.

Discovery of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides as potent agonists of TGR5 via sequential combinatorial libraries.

J. Warmus, M. Boehm, K. Futatsugi, 2013, Bioorganic & medicinal chemistry letters.

Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist.

Margaret S. Landis, D. Scott, P. Iredale, 2009, Journal of medicinal chemistry.

Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2).

C. C. Jorgensen, M. Boehm, D. Hepworth, 2015, Journal of medicinal chemistry.

Outcome after combined carotid endarterectomy and coronary artery bypass is related to patient selection.

W. Mackey, K. Khabbaz, J. Estes, 2001, Journal of vascular surgery.

Practical synthesis of capromorelin, a growth hormone secretagogue, via a crystallization-induced dynamic resolution.

B. Lefker, P. Carpino, Colin R. Rose, 2017, Bioorganic & medicinal chemistry.

Identification of spirocyclic piperidine-azetidine inverse agonists of the ghrelin receptor.

Z. Hendsch, B. Posner, D. Kung, 2012, Bioorganic & medicinal chemistry letters.

Dihydropyridines: A New Class of Angiotensin II Antagonists.

K. W. Hoover, M. Mangiapane, M. Burkard, 1994 .

Clinical benefits of endoscopic vein harvesting in patients with risk factors for saphenectomy wound infections undergoing coronary artery bypass grafting.

K. Khabbaz, K. Warner, R. Bojar, 2000, The Journal of thoracic and cardiovascular surgery.

Structural basis for AMPK activation: natural and synthetic ligands regulate kinase activity from opposite poles by different molecular mechanisms.

R. Kurumbail, M. Harris, Hong Wang, 2014, Structure.

Centrally Acting Anti-Obesity Agents

D. Hepworth, S. Black, P. Carpino, 2006 .